Understanding drug prices is challenging. Price drivers are difficult to determine and unexpected movements do occur, particularly during periods of healthcare reform, cost containment and austerity.
Our latest study Dynamic Pharmaceutical Pricing 2012: What’s Really Behind Drug Prices? presents an extensive global analysis of how and why pharmaceutical prices change. This study provides a clear and comprehensive overview of drug price changes within and across markets. Leveraging our proprietary POLI pricing database, the study analyses how and why ex-manufacturing prices have changed over time, as well as how pricing differs by therapeutic area and country, strengthening go-to-market and life-cycle management strategies.
This report provides a comprehensive and extensive analysis of pharmaceutical price changes and their drivers in 16 key developed and emerging markets. It also extends the analysis of pricing trends and selected case studies to 36 of the 42 countries included in the IHS Global Insight proprietary POLI pricing database.
Key questions answered include:
- How have drug prices, broken down by generic/branded product segment and across therapeutic areas, been evolving in recent years?
- What are the major drivers behind pharmaceutical price changes?
- How does healthcare reform, such as that seen in the United States and Germany, affect prices?
- What is the real impact of the global economic downturn on pharmaceutical prices?
- How does reference pricing, both international and therapeutic, impact drug prices?
- How has the much-vaunted patent cliff affected pricing dynamics?
- How will ongoing policy developments influence pharmaceutical price changes in future?